(physiological barrier between the brain and its blood vessels), dealing with consequent encephalitis through treatment becomes problematic.
To overcome these obstacles, the team created a New treatments using targeted ‘gene delivery’ systems to increase the number of specific anti-inflammatory immune cells in the brain to limit inflammation and brain damage.
Novel treatment of brain injury
“Our body has its own anti-inflammatory response, regulatory T cells, which are able to sense inflammation and produce a natural anti-inflammatory drug blend. Unfortunately, there are very few T cells. This regulation in the brain (due to a limited supply of the vital survival molecule interleukin 2, also known as IL2), so they are overwhelmed by post-traumatic inflammation. novel therapy to increase the population of regulatory T cells in the brain produced by brain cells), so that they can control inflammation and reduce injury-induced damage,” says Prof Liston, Babraham Institute said.
Effective novel viral vector technology crosses the blood-brain barrier to demonstrate its therapeutic benefit. The team also demonstrated the drug’s potential to successfully control brain inflammation in their mouse models of multiple sclerosis and stroke.
“By understanding and manipulating the immune response in the brain, we were able to develop the IL2 gene delivery system as a potential treatment for neuroinflammation. Tens of millions of people are affected each year. and very few treatment options, this has real potential to help people in need.We hope that this system will soon enter clinical trials, which is needed to test whether this approach whether the treatment is effective in the patient,” Professor Liston said.
Source: Medindia
